Kinetics of Acute Hepatitis B Virus Infection in Humans

Using patient data from a unique single source outbreak of hepatitis B virus (HBV) infection, we have characterized the kinetics of acute HBV infection by monitoring viral turnover in the serum during the late incubation and clinical phases of the disease in humans. HBV replicates rapidly with minimally estimated doubling times ranging between 2.2 and 5.8 d (mean 3.7 ± 1.5 d). After a peak viral load in serum of nearly 1010 HBV DNA copies/ml is attained, clearance of HBV DNA follows a two or three phase decay pattern with an initial rapid decline characterized by mean half-life (t 1/2) of 3.7 ± 1.2 d, similar to the t 1/2 observed in the noncytolytic clearance of covalently closed circular DNA for other hepadnaviruses. The final phase of virion clearance occurs at a variable rate (t 1/2 of 4.8 to 284 d) and may relate to the rate of loss of infected hepatocytes. Free virus has a mean t 1/2 of at most 1.2 ± 0.6 d. We estimate a peak HBV production rate of at least 1013 virions/day and a maximum production rate of an infected hepatocyte of 200–1,000 virions/day, on average. At this peak rate of virion production we estimate that every possible single and most double mutations would be created each day.

[1]  S. Sherlock,et al.  Diseases of the Liver and Biliary System , 1955 .

[2]  D. Vergani,et al.  Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms , 2000, Hepatology.

[3]  Capel,et al.  Evaluation of an enzyme‐linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA , 2000, Journal of viral hepatitis.

[4]  Rachel Hallett,et al.  Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy , 2000, The Lancet.

[5]  J. Pawlotsky,et al.  Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. , 2000, Journal of virological methods.

[6]  M. Kew Serum aminotransferase concentration as evidence of hepatocellular damage , 2000, The Lancet.

[7]  M. I. Barrasa,et al.  Apoptosis and Regeneration of Hepatocytes during Recovery from Transient Hepadnavirus Infections , 2000, Journal of Virology.

[8]  Douglas D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[9]  Anders Hedrum,et al.  Automated Quantitative Analysis of Hepatitis B Virus DNA by Using the Cobas Amplicor HBV Monitor Test , 1999, Journal of Clinical Microbiology.

[10]  H. Isom,et al.  Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of (−)-β-2′,3′-Dideoxy-3′-Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA , 1999, Antimicrobial Agents and Chemotherapy.

[11]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[12]  M. Shapiro,et al.  Viral clearance without destruction of infected cells during acute HBV infection. , 1999, Science.

[13]  L M Wahl,et al.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection , 1997, Journal of virology.

[14]  D. Miller,et al.  Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks. , 1996, Virology.

[15]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  S. Locarnini,et al.  The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo , 1996, Antimicrobial agents and chemotherapy.

[17]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[18]  S. Locarnini,et al.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes , 1995, Journal of virology.

[19]  K. Hyams Risks of chronicity following acute hepatitis B virus infection: a review. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[21]  S. Locarnini,et al.  The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. , 1994, Virology.

[22]  J. Hoofnagle,et al.  High levels of viral replication during acute hepatitis B infection predict progression to chronicity , 1994, Journal of medical virology.

[23]  N. Mcintyre Clinical presentation of acute viral hepatitis. , 1990, British Medical Bulletin.

[24]  S. Govindarajan,et al.  Serum hepatitis B viral DNA in acute viral hepatitis B. , 1989, Annals of Internal Medicine.

[25]  M. Manns,et al.  Pre-S encoded surface proteins in relation to the major viral surface antigen in acute hepatitis B virus infection. , 1987, Gastroenterology.

[26]  J. Summers,et al.  Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells , 1986, Cell.

[27]  B. Lacour,et al.  Immune lysis of hepatocytes in culture: accurate detection by aspartate aminotransferase release measurement. , 1984, Journal of immunological methods.

[28]  W. Gerlich,et al.  Large surface proteins of hepatitis B virus containing the pre-s sequence , 1984, Journal of virology.

[29]  J. Summers,et al.  Experimental transmission of duck hepatitis B virus. , 1983, Virology.

[30]  D. Vergani,et al.  Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. , 1982, Journal of immunology.

[31]  J. Summers,et al.  Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate , 1982, Cell.

[32]  W. Szmuness,et al.  A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report , 1981, Hepatology.